Transplantation
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients.
A randomized, double-blind study was conducted to evaluate the pharmacokinetics of ganciclovir following oral administration of ganciclovir or valganciclovir for prophylaxis of cytomegalovirus (CMV) disease in solid organ transplant recipients (n = 240/372). ⋯ The greater systemic exposure to ganciclovir delivered by valganciclovir was associated with delayed development of viremia. There was only a weak association between AUC and hematological toxicity.